Cut-off value to identify a flare using the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire: analysis of the TOSCA study.

FLARE-RA questionnaire disease activity flare patient reported outcome measure rheumatoid arthritis self-assessment

Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
24 12 2021
Historique:
pubmed: 1 4 2021
medline: 23 2 2022
entrez: 31 3 2021
Statut: ppublish

Résumé

The Flare Assessment in RA (FLARE-RA) self-administered questionnaire aims to identify patients who had flare in the interval between two consultations. This study aimed to establish a threshold for FLARE-RA score to identify RA flare. The Tocilizumab SubCutAneous study evaluated the efficacy and safety of s.c. tocilizumab (TCZ) to patients with active RA. Disease activity was assessed with the DAS28ESR at baseline and at week 2 (W2), W4, W12 and W24. The FLARE-RA questionnaire was administered at W12 and W24. Patient satisfaction, assessed at baseline and W24 with the Patient Acceptable Symptom State (PASS), was used as a surrogate marker of no flare. A correlation was sought between the FLARE-RA score at W12 and W24 and the area under the receiver operating characteristic (ROC) curve (AUC) for monthly DAS28ESR. The optimal FLARE-RA cut-off below which patient satisfaction reached the PASS was explored with an ROC curve. A total of 139 patients were included (mean age 57.3 ± 13.8 years, 74.1% women, mean RA duration 10.8 ± 9.2 years, mean DAS28ESR 5.8 ± 1.1). The correlation between the FLARE-RA score and DAS28ESR AUC was moderate at all times: ρ = 0.41 at W12 (P < 0.0001) and 0.51 at W24 (P < 0.0001). The optimal cut-off for the FLARE-RA score to identify absence of flare (i.e. an acceptable situation based on the PASS) was 2.3 with an AUC of 0.81. FLARE-RA and DAS28ESR assessment differ; we propose a FLARE-RA cut-off of 2.3, below which the situation (i.e. without flare) is acceptable for patients.

Identifiants

pubmed: 33788913
pii: 6206786
doi: 10.1093/rheumatology/keab261
doi:

Types de publication

Clinical Trial, Phase IV Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

337-344

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Krystel Aouad (K)

Rheumatology Department, Pitié Salpêtrière hospital, Sorbonne Université - Assistance Publique Hôpitaux de Paris, Paris, France.
Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.

Philippe Gaudin (P)

Rheumatology Department, Hôpital Sud, A Michallon, Echirolles, France.

Olivier Vittecoq (O)

Rheumatology & CIC-CRB 1404 Department, Rouen University Hospital and Normandie University, UNIROUEN, Rouen, France.

Jacques Morel (J)

Rheumatology Department, CHU and University of Montpellier, Montpellier, France.

Jean-Marie Berthelot (JM)

Rheumatology Department, CHU Nantes, Nantes, France.

Eric Senbel (E)

Rheumatology Department, Sainte Marguerite Hospital, Marseille, France.

Thierry Schaeverbeke (T)

Rheumatology Department, CHU Bordeaux, Université V Segalen, Bordeaux, France.

Frédéric Lioté (F)

Rhumatology Department, CHU Lariboisière, Centre Viggo Petersen, Université de Paris-AP-HP, Paris, France.

René-Marc Flipo (RM)

Rheumatology Department, Université de Lille, CHU Lille, Lille, France.

Alexandrine Pinta (A)

ROCHE, Boulogne Billancourt, France.

Francis Guillemin (F)

Inserm CIC 1433, Epidémiologie clinique, CHRU Nancy, Nancy, France.

Bruno Fautrel (B)

Rheumatology Department, Pitié Salpêtrière hospital, Sorbonne Université - Assistance Publique Hôpitaux de Paris, Paris, France.
Sorbonne University-INSERM, U1136-6, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH